| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on January 27, 2003
Accepted on April 22, 2003
1 Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE-75185 Uppsala, Sweden; Laboratory of Molecular Biology, National Cancer Institute, National Institutes of Health, Bethesda MD 20892, USA; Correspondence: Phone +46 18 611 0223, Fax +46 18 611 0222, email: magnus.essand@klinimm.uu.se
* To whom correspondence should be addressed. E-mail: magnus.essand{at}klinimm.uu.se.
TARP (T cell receptor
-chain alternate reading frame protein) is uniquely expressed in males in prostate epithelial cells and prostate cancer cells. Here we demonstrate that TARP expression is regulated by testosterone at the transcriptional level through specific binding of androgen receptor to an androgen response element in the proximal TARP promoter. We further demonstrate that the promoter specifically initiates reporter gene expression in TARP-positive prostate cancer cell lines. To develop a regulatory sequence for prostate-specific gene expression we constructed a chimeric sequence consisting of the TARP promoter and the PSA enhancer. We found that in the prostatic adenocarcinoma cell line LNCaP, the transcriptional activity of the regulatory sequence consisting of a TARP promoter and PSA enhancer is 20 times higher than the activity of a regulatory sequence consisting of the PSA promoter and the PSA enhancer. Thus, our studies define a regulatory sequence that may be used to restrict expression of therapeutic genes to prostate cancer cells and may therefore play a role in prostate cancer gene therapy.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |